• Home
  • » 
  • Reports
  • » 
  • Non-Opioid Drugs for Chronic Pain and Pain Management Devices Market | Industry Analysis | Market Size | 2025

Non-Opioid Drugs for Chronic Pain and Pain Management Devices Market, 2018-2025

  • Lowest Price Guaranteed From USD 3,499

  • Published
    August 2018

  • Pages
    340

  • View Count
    6885

  • Buy Now

Example Insights

 

Report Description

Currently, there too many deaths and side-effects reported due to over use of opioids. The shift from opioid to non-opioid is already happening. It is fair to state that a majority of the patients will use non-opioids rather than opioids in the next ten years

-Director, US based device manufacturer

Chronic pain refers to the psychophysiological response to an underlying clinical condition, which is observed to persist for a duration greater than six months and is generally unresponsive to multiple treatment regimens. It is estimated that more than 1.5 billion individuals across the world suffer from this type of pain. Some of the most common physiological conditions that are characterized by a chronic sensation of pain include migraine, lower back pain, pain associated with cancer, arthritis-related pain and neurogenic pain. Owing to the rapid onset of their medicinal effect, which offers immediate relief with high efficacy, opioids are still considered to be one of the most widely used pharmacological interventions for the management of moderate to severe forms of pain. However, these drugs are known to induce a euphoric state upon intake, often causing patients to abuse them; increased recreational use of opioids has also been shown to lead to drug addiction. The over-prescription of such medicinal products, which promotes their misuse, is considered as one of the root causes of the opioid crisis. In a recent article, published in 2017, 11.5 million individuals were reported to have been caught misusing prescription opioids, while over 42,000 died from opioid overdose, in the US alone. Moreover, opioid abuse was estimated to have been responsible for over USD 500 billion worth of economic deficit (in the US) due to loss of productivity and healthcare costs.

The opioid crisis has prompted drug manufacturers to develop non-addictive, non-narcotic-based therapeutics / analgesics for the management of pain. Unlike opioids, non-opioid drugs do not affect receptors present in the brain and, thus, are not addictive. These drugs work directly on injured / diseased body tissues and generally block the production of prostaglandins by inhibiting the cyclooxygenase (COX) enzyme at the site of injury / infection, thereby, decreasing the generation of pain mediators within the peripheral nervous system. Additionally, there are various pain management devices that have been reported to significantly reduce or eliminate the need for pharmacological interventions. Such devices are increasingly being used to treat a variety of clinical conditions that are characterized by chronic pain and offer the convenience of being used in the homecare setting as well. However, it is imperative for patients to consult qualified healthcare professionals, who have the required understanding of such therapeutic options, prior to using such devices.

 

Scope of the Report

The “Non-Opioid Drugs for Chronic Pain and Pain Management Devices Market, 2018-2025” report provides an extensive study on the marketed, clinical and preclinical products / product candidates for management of chronic pain. The report also features a detailed overview of the devices that are used for the treatment / management of pain associated with chronic clinical conditions. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of drugs being developed for the treatment of chronic pain, providing information on their respective developer(s), phase of development (clinical, and preclinical / discovery), type of molecule (small molecule and biologic), indication (nociceptive and neuropathic), mechanism of action (channel blockers, receptor antagonists, protein pathway modulators and others) and route of administration (intra-articular, intravenous, intranasal,  intranasal, intrathecal, oral, subcutaneous, topical and transdermal).
  • An in-depth analysis of the product pipeline and developer companies, featuring [A] a mirror analysis highlighting the relative popularity of different disease indications based on the number of molecules available / under development for each indication and the number of companies involved, [B] a logo landscape of the various industry players involved in this domain, distributed on the basis of location of headquarters and company size (small-sized, mid-sized and large), [C] a heptagon representation highlighting the distribution of marketed and pipeline molecules based on their respective mechanisms of action, and [D] a funnel analysis highlighting the distribution of molecules on the basis of stage of development, route of administration and treatment type.
  • An analysis highlighting the key unmet needs across chronic pain, featuring insights generated from data sourced from patient blogs, recent scientific publications, social media posts and the views of key opinion leaders expressed on various online platforms.
  • An elaborate discussion on lifecycle management strategies, describing how different companies are using various methods to prolong patent age and, thereby, expand marketing exclusivity in order to exploit the revenue generation potential of their proprietary products. The section also includes detailed case studies elaborating on diverse lifecycle management strategies of marketed drugs that are nearing patent expiry.
  • Comprehensive profiles of drugs that are in phase III of clinical development, with information on developer companies (including location of headquarters and year of establishment), type of molecule, mechanism of action, current status of development, route of administration, information on clinical trials and key developments (if available).
  • A detailed assessment of the current market landscape of various devices that are being developed for chronic pain management, highlighting information on developer (size of company and location of headquarters), mechanism of action (electrical stimulation, electromagnetic pulse, heat therapy, light therapy, radiofrequency stimulation and others), site of application on the body (head, arm, knees and other areas), modality of the device (invasive and non-invasive), and treatment requirements (at home and at hospitals / outpatient clinics), and type of device (wearable, hand-held and implants).
  • An insightful 2X2 competitive analysis for the various devices, highlighting the most important products based on the modality of device, treatment requirement, type of device, and supplier power (based on size of employee base of the company). The chapter also includes profiles of devices that emerged as relatively superior (based on the analysis); each profile features details on the developer (location of headquarters and year of establishment), approval year, mechanism of action, key features and key developments.
  • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements (related to both technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements and others
  • An analysis of investments made at various stages of product development; these include seed financing, venture capital financing, debt financing and grants / awards, received by companies that are operating in this domain.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term, for the period 2018-2025. The report includes a detailed market segmentation on the basisof indication (chronic back pain, lumbar radiculopathy, migraine, osteoarthritis and neuropathic pain), type of molecule (small  molecule and biologic), mechanism of action (CGRP inhibitors, COX/ NGF inhibitors, TRPV1 receptor antagonists, channel blockers and others) and geography (North America, Europe, Asia Pacific and rest of the World). In addition, the report features an opportunity analysis for the chronic pain management devices market. The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Ryan Jeffcoat (Director of Clinical Affairs & New Markets, AVACEN Medical), Lisa Robin (Chief Advocacy Officer, Federation of State Medical Boards), Nelson Hendler (Chief Executive Officer, Mensana Clinic Diagnostics) and Mark Wiederhold (Chief Executive Officer, Virtual Reality Medical Center). All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the non-opioid drugs and pain management devices market, in the mid-long term.

Chapter 3  provides an introduction to chronic pain and associated disease indications. It features a detailed discussion on the classification of pain, and affiliated symptoms and causes. The section also highlights the available therapeutic options for the treatment / management of this clinical condition. In addition, it summarizes the reasons for the opioid crisis, and the steps being taken within healthcare domain to develop and introduce alternative, non-opioid-based therapeutic strategies.

Chapter 4  highlights the key unmet needs associated with the management and treatment of chronic pain. The chapter provides a detailed analysis of such needs as identified from views expressed by patients / industry experts across different platforms, such as patient blogs, recent scientific publications, social media posts and as discussed by key opinion leaders at various conferences / symposiums. The chapter also presents an insightful sentiment analysis and word cloud analyses, summarizing the diverse opinions expressed across the aforementioned public portals.

Chapter 5  includes information on over 160 non-opioid molecules that are currently approved / under development for therapeutic use. It features a comprehensive analysis of marketed and pipeline molecules, highlighting the phase of development (clinical and preclinical / discovery stage) of product candidates, type of molecule (small molecule and biologic), sub-indication (nociceptive and neuropathic) mechanism of action, route of administration and information on the developer companies (including location of headquarters and year of establishment). In addition, it presents a set of key insights derived from a mirror analysis, highlighting the relative popularity of the different indications based on the number of molecules available / under development for each indication and the number of companies involved. The chapter also features a heptagon representation highlighting the distribution of the marketed and pipeline molecules based on different mechanisms of action and a logo landscape of the various industry players involved in this market, distributed on the basis of location of headquarters and company size (small-sized, mid-sized and large). Additionally, the chapter features a funnel analysis highlighting the distribution of molecules on the basis of stage of development, route of administration and treatment type.

Chapter 6  includes a detailed discussion on product life cycle management strategies that are being considered by developers of already approved / marketed drugs. It focuses on specific strategies, which are used by drug developers in this domain, to expand patent protection and retain the revenue generation potential of their proprietary products without having to contend with the competition that is likely to be generated by generic versions.

Chapter 7  contains detailed profiles of drugs that are in phase III of clinical development. Each profile features an overview of the developer, information on the route of administration, type of molecule, mechanism of action, current status of development, key clinical trials and key recent developments ( wherever available ).

Chapter 8  includes information on close to 120 devices that are currently approved / under investigation for the treatment / management of chronic pain. It also features a comprehensive analysis of the information on developer (size of company and location of headquarters), mechanism of action, site of application on the body (head, arm, knees and other areas), modality of the device (invasive and non-invasive), treatment requirement (at home and at hospitals / outpatient clinics), type of device (wearable, hand-held and implants) and mechanism of action of device (electrical stimulation, radiofrequency stimulation, heat therapy and others) .

Chapter 9  provides a comprehensive 2X2 analysis featuring a comparative overview of all the available / under development devices for chronic pain management. The analysis compares the products based on the modality of device, treatment requirement, type of device, supplier power (based on size of employee base of the company). Further, the chapter features detailed profiles of devices which appeared to be relatively superior to other products / product candidates. Each of these profiles include details on their developer (location of headquarters and year of establishment), approval year of the product, mechanism of action, key features and key developments.

Chapter 10  features an analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed the different partnership models (including product development and commercialization, R&D agreements, technology / product licensing agreements, other licensing agreements, mergers / acquisitions and clinical trial collaborations) and the most common forms of deals / agreements that have been established between 2012 to 2018.

Chapter 11  presents details on various investments received by small sized companies that are engaged in this domain. It also includes a detailed analysis of the funding instances that have taken place between January 2001 and April 2018, highlighting the growing interest of the venture capital community and other strategic investors in this domain.

Chapter 12  presents a comprehensive market forecast analysis, highlighting the future potential of non-opioid drugs in chronic pain market, till the year 2025. We have segregated the opportunity on the basis of indication (chronic back pain, lumbar radiculopathy, migraine, osteoarthritis and neuropathic pain), type of molecule (small molecule and biologic), mechanism of action (CGRP inhibitors, COX/ NGF inhibitors, TRPV1 receptor antagonists, channel blockers and others) and geography (North America, Europe, Asia Pacific and rest of the World). Future sales potential and growth opportunity were estimated based on likely adoption rates and the anticipated price of products. The report features an opportunity analysis for chronic pain management devices as well.

Chapter 13  summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14  is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with ( in alphabetical order of company name ) Ryan Jeffcoat (Director of Clinical Affairs & New Markets, AVACEN Medical), Lisa Robin (Chief Advocacy Officer, Federation of State Medical Boards), Nelson Hendler (Chief Executive Officer, Mensana Clinic Diagnostics), and Mark Wiederhold (Chief Executive Officer, Virtual Reality Medical Center).

Chapter 15  is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16  is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Definition of Pain
3.2. Classification of Pain
3.2.1. Acute Pain
3.2.2. Chronic Pain
3.2.2.1. Classification of Chronic Pain
3.2.2.2. Chronic Pain and Mental Health
 
3.3. Pain Management
3.3.1. Therapeutics for Pain Management
3.3.2. Devices for Pain Management
3.3.3. Other Therapeutic Modalities and Interventions for Pain Management
3.4. Future Prospects
 
4. CHRONIC PAIN MANAGEMENT: UNMET NEED ANALYSIS
4.1. Chapter Overview
4.2. Unmet Need Analysis
4.2.1. Introduction
4.2.2. Patient Blogs
4.2.2.1. Methodology
4.2.2.2. Key Insights
 
4.2.3. Published Literature
4.2.3.1. Methodology
4.2.3.2. Key Insights
 
4.2.4. Social Media Platforms
4.2.4.1. Methodology
4.2.4.2. Key Insights
 
4.2.5. Expert Opinions
4.2.5.1. Jeffrey Curtis, MD, University of Alabama
4.2.5.2. Stephan Silberstein, MD, Jefferson University Hospital
4.2.5.3. Jeffrey Gudin, MD, Englewood Hospital and Medical Center
4.2.5.4. Kevin Zacharoff, MD, SUNY Stonybrook School of Medicine
4.2.5.5. Philip J Mease, MD, University of Washington School of Medicine
4.2.5.6. John D Reveille, MD, McGovern Medical School
4.2.5.7. Christopher R McCurdy, PhD, University of Florida
 
4.2.6. Concluding Remarks: Key Unmet Needs in Chronic Pain Management
 
5. PIPELINE REVIEW: MARKETED AND DEVELOPMENT DRUGS
5.1. Chapter Overview
5.2. Non-Opioid Drugs for Chronic Pain Management: Marketed and Development Pipeline
5.3. Non-Opioid Drugs for Chronic Pain Management: Pipeline Analysis
5.3.1. Analysis by Phase of Development
5.3.2. Analysis by Type of Molecule
5.3.3. Analysis by Mechanism of Action
5.3.4. Analysis by Route of Administration
5.3.5. Analysis by Target Therapeutic Indication(s)
5.3.6. Analysis by Size of Employee Base of Developer
5.3.7. Pipeline Analysis: Leading Players
5.3.8. Developer Logo Landscape: Distribution by Size and Location
5.3.9. Mirror Analysis: Distribution by Type of Indication, Number of Molecules and Manufacturer
5.3.10. Heptagon Representation: Distribution by Target Disease Indication and Phase of Development
5.3.11. Funnel Analysis: Distribution by Target Disease Indications, Route of Administration and Phase of Development
 
6. LIFECYCLE MANAGEMENT STRATEGIES FOR MARKETED PRODUCTS
6.1. Introduction
6.2. Product Profile: Duexis® (Horizon Pharma)
6.2.1. Overview
6.2.2. Mechanism of Action
6.2.3. Life Cycle Management Strategies
6.2.3.1. Strategic Pricing
6.2.3.2. Geographical Expansion
6.2.3.3. Indication Expansion
6.2.3.4. Extension of Patent Exclusivity
6.2.3.5. Authorized Generics
6.2.3.6. Awareness Campaigns
6.2.4. Partnerships and Collaborations
6.2.4.1. Mallinckrodt
6.2.4.2. Grü nenthal
 
6.3. Product Profile: Gralise® (Depomed)
6.3.1. Overview
6.3.2. Mechanism of Action
6.3.3. Life Cycle Management Strategies
6.3.3.1. New Dose Strength
6.3.4. Legal Defense
6.3.4.1. Authorized Generics
6.3.5. Partnerships and Collaborations
6.3.5.1. Actavis
6.3.5.2. Abbott
 
6.4. Product Profile: Horizant® (Arbor Pharmaceuticals)
6.4.1. Overview
6.4.2. Mechanism of Action
6.4.3. Life Cycle Management Strategies
6.4.3.1. Extension of Patent Exclusivity
6.4.3.2. Indication Expansion
6.4.4. New Dose Strength
6.4.5. Partnerships and Collaborations
6.4.5.1. GlaxoSmithKline
6.4.5.2. Arbor Pharmaceutical
 
6.5. Product Profile: Vimovo® (AstraZeneca and Pozen)
6.5.1. Overview
6.5.2. Mechanism of Action
6.5.3. Life Cycle Management Strategies
6.5.3.1. Pricing
6.5.3.2. Geographical Expansion
6.5.4. Legal Defense
6.5.5. Partnerships and Collaborations
6.5.5.1. AstraZeneca
6.5.5.2. Horizon Pharma
 
7. DRUG PROFILES: LATE STAGE MOLECULES
7.1. Chapter Overview
7.2. Drug Profile: Aimovig™ / Erenumab
7.3. Drug Profile: Analgecine
7.4. Drug Profile: Atogepant / AGN 241689 / MK 8031
7.5. Drug Profile: Civamide / Civanex / Zucapsaicin
7.6. Drug Profile: CNTX-4975
7.7. Drug Profile: Eptinezumab / ALD403
7.8. Drug Profile: Fasinumab
7.9. Drug Profile: Fremanezumab
7.10. Drug Profile: Galcanezumab / LY2951742
7.11. Drug Profile: Lasmiditan / COL-144
7.12. Drug Profile: Mirogabalin / DS-5565
7.13. Drug Profile: MPC-06-ID
7.14. Drug Profile: Neridronate
7.15. Drug Profile: NTM-001
7.16. Drug Profile: NTM-002
7.17. Drug Profile: Perampanel (E2007)
7.18. Drug Profile: POSIMIR (SABER-Bupivacaine)
7.19. Drug Profile: Ralfinamide
7.20. Drug Profile: SP-102
7.21. Drug Profile: T-121
7.22. Drug Profile: Tanezumab
7.23. Drug Profile: Tetrodotoxin / TTX
7.24. Drug Profile: Ubrogepant / MK-1602
7.25. Drug Profile: YHD1119 / PREGABALIN
 
8. CHRONIC PAIN MANAGEMENT DEVICES: MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Devices for Pain Management: Database
8.3. Devices for Pain Management: Database Analysis
8.3.1. Analysis by Type of Devices
8.3.2. Analysis by Mechanism of Action
8.3.3. Analysis by Modality of Device
8.3.4. Analysis by Site of Application on Body
8.3.5. Analysis by Convenience of Use
8.3.6. Analysis by Location of Developer(s)
8.3.7. Analysis by Company Size
 
9. DEVICE COMPETITIVENESS ANALYSIS AND PROFILES
9.1. Chapter Overview
9.2. Methodology
9.3. Implants
9.3.1. Assumptions, Limitations and Key Evaluable Parameters
9.3.2. Device Competitive Analysis for Implants: Results
9.3.3. Device Profiles
9.3.3.1. Freedom SCS System (Stimwave)
9.3.3.2. VIVENDI™ (BlueWind Medical)
 
9.4. Wearables
9.4.1. Assumptions, Limitations and Parameters Evaluated
9.4.2. Device Competitive Analysis for Wearables: Results
9.4.3. Device Profiles
9.4.3.1. Avail Wireless (Omron Healthcare)
9.4.3.2. Cefaly (Cefaly Technologies)
9.4.3.3. Electro-Mesh Garments (Prizm Medical)
9.4.3.4. Micro-Z (Prizm Medical)
9.4.3.5. PainPod MI (PainPod)
9.4.3.6. PainPod XPV (PainPod)
9.4.3.7. Quell Relief (Neurometrix)
9.4.3.8. SENSUS®  Pain Management System (Neurometrix)
9.4.3.9. Smart Relief Back (Chattem)
 
9.5. Other Devices
9.5.1. Assumptions, Limitations and Parameters Evaluated
9.5.2. Devices Competitive Analysis for Other Devices: Results
9.5.3. Device Profiles
9.5.3.1. Silk’n Relief (Silk’n Therapy)
9.5.3.2. The Wellness Pro™ Plus (ElectroMedical Technologies)
 
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Non-Opioid Drugs and Devices for Chronic Pain Management: Recent Partnerships and Collaborations
10.3.1. Analysis by Year of Agreement
10.3.2. Analysis by Quarterly Trends
10.3.3. Analysis by Type of Partnership
10.3.4. Analysis by Most Active Players
10.3.5. Analysis by Geographical Activity
 
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Non-Opioid Drugs for Chronic Pain Management: Funding and Investment Analysis
11.3.1. Analysis by Cumulative Number of Funding Instances
11.3.2. Analysis by Cumulative Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Analysis by Most Active Players
11.3.5. Analysis by Most Active Investors
11.4. Concluding Remarks
 
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions
12.3. Forecast Methodology
12.4. Overall Non-Opioids Drugs for Chronic Pain Management Market, 2018-2025
12.4.1. Non-Opioid Drugs Market: Distribution by Therapeutic Area
12.4.2. Non-Opioid Drugs Market: Distribution by Molecule Type
12.4.3. Non-Opioid Drugs Market: Distribution by Mechanism of Action
12.4.4. Non-Opioid Drugs Market: Distribution by Geography
 
12.5. Non-Opioid Drugs Market: Product-Wise Sales Forecasts
12.5.1. Qutenza® (Accorda Therapeutics)
12.5.1.1. Drug Overview and Target Patient Population
12.5.1.2. Sales Forecast
 
12.5.2. Vimovo® (Horizon Pharma)
12.5.2.1. Drug Overview and Target Patient Population
12.5.2.2. Sales Forecast
 
12.5.3. Duexis® (Horizon Pharma)
12.5.3.1. Drug Overview and Target Patient Population
12.5.3.2. Sales Forecast
 
12.5.4. Gralise® (Depomed)
12.5.4.1. Drug Overview and Target Patient Population
12.5.4.2. Sales Forecast
 
12.5.5. Horizant® (Arbor Pharmaceuticals)
12.5.5.1. Drug Overview and Target Patient Population
12.5.5.2. Sales Forecast
 
12.5.6. Zilretta® (Flexion Therapeutics)
12.5.6.1. Drug Overview and Target Patient Population
12.5.6.2. Sales Forecast
 
12.5.7. Ztlido™ (Sorrento Therapeutics)
12.5.7.1. Drug Overview and Target Patient Population
12.5.7.2. Sales Forecast
 
12.5.8. Aimovig™ (Amgen)
12.5.8.1. Drug Overview and Target Patient Population
12.5.8.2. Sales Forecast
 
12.5.9. Fremanezumab (Teva Pharmaceuticals)
12.5.9.1. Drug Overview and Target Patient Population
12.5.9.2. Sales Forecast
 
12.5.10. Galcanezumab (Eli Lilly)
12.5.10.1. Drug Overview and Target Patient Population
12.5.10.2. Sales Forecast
 
12.5.11. Mirogabalin (DS-5565) (Daiichi Sankyo)
12.5.11.1. Drug Overview and Target Patient Population
12.5.11.2. Sales Forecast
 
12.5.12. YHD1119 (Yuhan corporation)
12.5.12.1. Drug Overview and Target Patient Population
12.5.12.2. Sales Forecast
 
12.5.13. GLA5PR (GL PharmTech)
12.5.13.1. Drug Overview and Target Patient Population
12.5.13.2. Sales Forecast
 
12.5.14. Eptinezumab (Alder Biopharmaceuticals)
12.5.14.1. Drug Overview and Target Patient Population
12.5.14.2. Sales Forecast
 
12.5.15. ALLOD-2 (Allodynic Therapeutics)
12.5.15.1. Drug Overview and Target Patient Population
12.5.15.2. Sales Forecast
 
12.5.16. PainBrake® (GT Biopharma)
12.5.16.1. Drug Overview and Target Patient Population
12.5.16.2. Sales Forecast
 
12.5.17. Neridronate (Grunenthal)
12.5.17.1. Drug Overview and Target Patient Population
12.5.17.2. Sales Forecast
 
12.5.18. Fasinumab (Regeneron Pharmaceuticals)
12.5.18.1. Drug Overview and Target Patient Population
12.5.18.2. Sales Forecast
 
12.5.19. SP-102 (Semnur Pharmaceuticals)
12.5.19.1. Drug Overview and Target Patient Population
12.5.19.2. Sales Forecast
 
12.5.20. CNTX-4975 (Centrexion Therapeutics)
12.5.20.1. Drug Overview and Target Patient Population
12.5.20.2. Sales Forecast
 
12.5.21. MPC-06-ID (Mesoblast)
12.5.21.1. Drug Overview and Target Patient Population
12.5.21.2. Sales Forecast
 
12.5.22. Tanezumab
12.5.22.1. Drug Overview and Target Patient Population
12.5.22.2. Sales Forecast
 
12.6. Overall Pain Management Devices Market, 2018-2025
12.6.1. Pain Management Devices Market: Distribution by Geography
12.6.2. Pain Management Devices Market: Distribution by Type of Device
12.6.3. Pain Management Devices Market: Distribution by Mechanism of Action
 
13. CONCLUSION
13.1. The Opioid Crisis is Responsible for a Number of Fatalities Due to the Abuse of Controlled Substances; Drug Developers are Actively Attempting to Develop Alternative Pain Management Solutions
13.2. The Non-Opioid Therapeutics Market is Characterized by a Robust Pipeline of Candidate Drugs Being Developed for a Variety of Chronic Clinical Conditions
13.3. A Variety of Innovative Devices are also Available for the Management of Various Clinical Conditions Characterized by Chronic Pain
13.4. Increasing Partnership Activity and Financial Support from Various Investors are Indicative of Lucrative Future Potential
13.5. Given the Existing Unmet Needs, the Market is Anticipated to Grow at a Steady Pace in the Foreseen Future
 
14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Mark Wiederhold, Chief Executive Officer, Virtual Reality Medical Center (Q2 2018)
14.3. Lisa Robin, Chief Advocacy Officer, Federation of State Medical Boards (Q2 2018)
14.4. Nelson Hendler, Chief Executive Officer, Mensana Clinic Diagnostics (Q2 2018)
14.5. Ryan Jeffcoat, Director of Clinical Affairs and New Markets, AVACEN Medical (Q1 2018)
 

 

List of  Figures

Figure 3.1  Classification of Pain: Acute and Chronic Pain
Figure 3.2  Acute and Chronic Pain: Key Biological Pathways
Figure 3.3  Patient Assessment for Pain Intensity Pre- and Post-Operation
Figure 3.4  Chronic Pain: Primary Symptoms and Causes
Figure 3.5  Types of Chronic Pain: ICD Classification
Figure 3.6  Medications used for Chronic Pain Management in US, 2014-2015
Figure 3.7  Pain Management Therapeutics: Mode of Action
Figure 3.8  Primary Routes of Administration for Opioid Intake
Figure 3.9  Types of Pain Management Devices
Figure 4.1  Unmet Need Analysis: Overview of the Methodology
Figure 4.2  Unmet Needs in Chronic Pain Management: Word Cloud Analysis of Patient Blogs
Figure 4.3  Unmet Needs in Chronic Pain Management: Number of Publications, Year-wise Trend
Figure 4.4  Unmet Needs in Chronic Pain Management: Unmet Needs Highlighted in Published Literature
Figure 4.5  Social Media Analysis: Overview of the Keywords
Figure 4.6  Unmet Needs in Chronic Pain Management: Social Media Sentiment Analysis
Figure 4.7  Unmet Needs in Chronic Pain Management: Social Media Word Cloud on Total Tweets
Figure 4.8  Unmet Needs in Chronic Pain Management: Trends on Social Media
Figure 4.9  Unmet Needs in Chronic Pain Management: Most Prolific Authors on Social Media
Figure 4.10  Unmet Needs in Chronic Pain Management: Social Media Word Clouds on Most Popular Keywords
Figure 4.11  Summary of Key Unmet Needs in Chronic Pain 
Figure 5.1  Pipeline Analysis: Distribution by Phase of Development
Figure 5.2  Pipeline Analysis: Distribution by Type of Molecule
Figure 5.3  Pipeline Analysis: Distribution by Mechanism of Action
Figure 5.4  Pipeline Analysis: Distribution by Route of Administration
Figure 5.5  Pipeline Analysis: Distribution by Target Therapeutic Indications(s)
Figure 5.6  Pipeline Analysis: Distribution by Size of Employee Base of Developer
Figure 5.7  Pipeline Analysis: Distribution by Leading Players
Figure 5.8  Developer Logo Landscape: Distribution by Size and Location
Figure 5.9  Mirror Analysis: Distribution by Target Therapeutics Indication(s), Number of Molecules and Number of Developers
Figure 5.10  Heptagon Representation: Distribution by Target Disease Indications Indication(s) and Development Stage
Figure 5.11  Funnel Analysis: Distribution by Target Disease Indication, Route of Administration and Phase of Development
Figure 6.1  Types of Life Cycle Management Strategies
Figure 6.2  Duexis®: Mechanism of Action
Figure 6.3  Duexis®: Life Cycle Management Strategies
Figure 6.4  Gralise®: Mechanism of Action
Figure 6.5  Gralise®: Life Cycle Management Strategies
Figure 6.6  Horizant®: Mechanism of Action
Figure 6.7  Horizant®: Life Cycle Management Strategies
Figure 6.8  Vimovo®: Mechanism of Action
Figure 6.9  Vimovo®: Life Cycle Management Strategies
Figure 8.1  Devices for Pain Management: Distribution by Type 
Figure 8.2  Devices for Pain Management: Distribution by Mechanism of Action
Figure 8.3  Devices for Pain Management: Distribution by Administration Modality
Figure 8.4  Devices for Pain Management: Distribution by Site of Application on Body
Figure 8.5  Devices for Pain Management: Distribution by Convenience of Use
Figure 8.6  Devices for Pain Management: Distribution by Location of Developer(s)
Figure 8.7  Devices for Pain Management: Distribution by Company Size
Figure 9.1  Pain Management Device Competitiveness Analysis: Methodology
Figure 9.2  Device Competitiveness Analysis for Implants: Dot-Plot Representation
Figure 9.3  Device Competitiveness Analysis for Wearables: Dot-Plot Representation
Figure 9.4  Device Competitiveness Analysis for Other Devices: Dot-Plot Representation
Figure 10.1  Recent Collaborations: Distribution by Year of Agreement
Figure 10.2  Recent Collaborations: Distribution by Quarterly Trends
Figure 10.3  Recent Collaborations: Distribution by Type of Partnership
Figure 10.4  Recent Collaborations: Distribution by Most Active Players
Figure 10.5  Recent Collaborations: Distribution by Geographical Activity
Figure 11.1  Non-Opioid Drugs for Chronic Pain Management: Cumulative Number of Funding Instances, 2010-2018
Figure 11.2  Non-Opioid Drugs for Chronic Pain Management: Cumulative Distribution of Amount Invested by Year, 2010-2018 (USD Million)
Figure 11.3  Non-Opioid Drugs for Chronic Pain Management: Distribution by Type of Funding, 2010-2018
Figure 11.4  Non-Opioid for Chronic Pain Management: Distribution of Total Amount Invested by Type of Funding, 2010-2018 (USD Million)
Figure 11.5  Non-Opioid Drugs for Chronic Pain Management: Most Active Players by Number of Funding Instances
Figure 11.6  Non-Opioid Drugs for Chronic Pain Management: Most Active Investors by Number of Funding Instances
Figure 11.7  Non-Opioid Drugs for Chronic Pain Management: Funding and Investment Summary
Figure 12.1  Non-Opioid Drugs for Chronic Pain Management Market: Base Scenario, 2018-2025 (USD Billion)
Figure 12.2  Non-Opioid Drugs for Chronic Pain Management Market: Distribution by Therapeutic Area, 2018-2025 (USD Billion)
Figure 12.3  Non-Opioid Drugs for Chronic Pain Management Market: Distribution by Molecule Type, 2018-2025 (USD Billion)
Figure 12.4  Non-Opioid Drugs for Chronic Pain Management Market: Distribution by Geography, 2018-2025 (USD Billion)
Figure 12.5  Qutenza® Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.6  Vimovo® Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.7  Duexis® Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.8  Gralise® Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.9  Horizant® Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.10  Zilretta® Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.11  Ztlido™ Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.12  Aimovig™ Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.13  Fremanezumab Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.14  Galcanezumab Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.15  Mirogabalin Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.16  YHD1119 Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.17  GLA5PR Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.18  Eptinezumab Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.19  ALLOD-2 Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.20  PainBrake® Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.21  Neridronate Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.22  Fasinumab Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.23  SP-102 Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.24  CNTX-4975 Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.25  MPC-06-ID Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.26  Tanezumab Sales Forecast (2018-2025): Base Scenario (USD Million)
Figure 12.27  Chronic Pain Management Devices Market: Base Scenario, 2018-2025 (USD Billion)
Figure 12.28  Chronic Pain Management Devices Market: Distribution by Geography, 2018-2025 (USD Billion)
Figure 12.29  Chronic Pain Management Devices Market: Distribution by Type of Device, 2018-2025 (USD Billion)
Figure 12.30  Chronic Pain Management Devices Market: Distribution by Mechanism of Action, 2018-2025 (USD Billion)
Figure 13.1  Non-Opioid Drugs for Chronic Pain Management Market: Summary of Base, Conservative and Optimistic Scenarios, 2018, 2022 and 2025 (USD Million)

List of Tables

Table 3.1 A Comparison of Chronic and Acute Pain
Table 3.2 Pain Management: WHO Pain Ladder
Table 3.3 A Comparison of Opioid and Non-Opioid Drugs
Table 3.4 Interventional Strategies for Pain Management
Table 5.1 Non-Opioid Drugs for Chronic Pain Management: Marketed and Development Pipeline
Table 7.1 Non-Opioid Drugs for Chronic Pain Management: Late-Stage Molecules
Table 7.2 Drug Profile: Aimovig™ / Erenumab
Table 7.3 Drug Profile: Analgecine
Table 7.4 Drug Profile: Atogepant / AGN 241689 / MK 8031
Table 7.5 Drug Profile: Civanex / Civamide / Zucapsaicin
Table 7.6 Drug Profile: CNTX-4975
Table 7.7 Drug Profile: Eptinezumab / ALD403
Table 7.8 Drug Profile: Fasinumab
Table 7.9 Drug Profile: Fremanezumab
Table 7.10 Drug Profile: Galcanezumab / LY2951742
Table 7.11 Drug Profile: Lasmiditan / COL-144
Table 7.12 Drug Profile: Mirogabalin / DS-5565
Table 7.13 Drug Profile: MPC-06-ID
Table 7.14 Drug Profile: Neridronate
Table 7.15 Drug Profile: NTM-001
Table 7.16 Drug Profile: NTM-002
Table 7.17 Drug Profile: Perampanel (E2007)
Table 7.18 Drug Profile: POSIMIR (SABER-Bupivacaine)
Table 7.19 Drug Profile: Ralfinamide
Table 7.20 Drug Profile: SP-102
Table 7.21 Drug Profile: T-121
Table 7.22 Drug Profile: Tanezumab
Table 7.23 Drug Profile: Tetrodotoxin / TTX
Table 7.24 Drug Profile: Ubrogepant / MK-1602
Table 7.25 Drug Profile: YHD1119 / Pregabalin
Table 8.1 List of Pain Management Devices
Table 9.1 Device Profiles: Implants
Table 9.2 Device Profile: Freedom SCS System
Table 9.3 Device Profile: VIVENDI™
Table 9.4 Device Profiles: Wearables
Table 9.5 Device Profile: Avail Wireless
Table 9.6 Device Profile: Cefaly
Table 9.7 Device Profile: Electro-Mesh Garments
Table 9.8 Device Profile: Micro-Z
Table 9.9 Device Profile: PainPod MI
Table 9.10 Device Profile: PainPod XPV
Table 9.11 Device Profile: Quell Relief
Table 9.12 Device Profile: SENSUS® Pain Management System
Table 9.13 Device Profile: Smart Relief Back
Table 9.14 Device Profiles: Other Devices
Table 9.15 Device Profile: Silk’n Therapy
Table 9.16 Device Profile: The Wellness Pro™ Plus
Table 10.1 Non-Opioid Drugs and Devices for Chronic Pain Management: Recent Partnerships and Coll
Table 11.1 Non-Opioid Drugs and Devices for Chronic Pain Management: Funding and Investments
Table 11.2 Non-Opioid Drugs and Devices for Chronic Pain Management: Summary of Investments
Table 12.1 Non-Opioid Drugs for Chronic Pain Management Market: Forecasted Candidates
Table 15.1 Patient Assessment for Pain Intensity Pre- and Post-Operation
Table 15.2 Medication used for Chronic Pain Management in US, 2014-2015
Table 15.3 Unmet Needs in Chronic Pain Management: Number of Publications, Year-wise Trend
Table 15.4 Unmet Needs in Chronic Pain Management: Information Available in Published Literature
Table 15.5 Social media Analysis: Overview of the Keywords
Table 15.6 Unmet Needs in Chronic Pain Management: Social Media Sentiment Analysis
Table 15.7 Unmet Needs in Chronic Pain Management: Most Prolific Authors on Social Media
Table 15.8 A Summary of Key Unmet Needs in Chronic Pain
Table 15.9 Pipeline Analysis: Distribution by Phase of Development
Table 15.10 Pipeline Analysis: Distribution by Type of Molecule
Table 15.11 Pipeline Analysis: Distribution by Mechanism of Action
Table 15.12 Pipeline Analysis: Distribution by Route of Administration
Table 15.13 Pipeline Analysis: Distribution by Target Therapeutic Indication(s)
Table 15.14 Pipeline Analysis: Distribution by Size of Employee Base of Developer
Table 15.15 Pipeline Analysis: Distribution by Leading Players
Table 15.16 Mirror Analysis: Distribution by Type of Indications, Number of Molecules and Manufact
Table 15.17 Heptagon Representation: Distribution by Target Disease Indication and Phase of Develo
Table 15.18 Devices for Pain Management: Distribution by Type
Table 15.19 Devices for Pain Management: Distribution by Mechanism of Action
Table 15.20 Devices for Pain Management: Distribution by Administration Modality
Table 15.21 Devices for Pain Management: Distribution by Site of Application on Body
Table 15.22 Devices for Pain Management: Distribution by Convenience of Use
Table 15.23 Devices for Pain Management: Distribution by Location of Developer(s)
Table 15.24 Devices for Pain Management: Distribution by Company Size
Table 15.25 Device Competitive Analysis for Implants: Dot-Plot Representation
Table 15.26 Device Competitive Analysis for Wearables: Dot-Plot Representation
Table 15.27 Device Competitive Analysis for Other Devices: Dot-Plot Representation
Table 15.28 Non-Opioid Drugs and Devices for Chronic Pain Management: Distribution by Year of Agree
Table 15.29 Non-Opioid Drugs and Devices for Chronic Pain Management: Distribution by Quarterly Tr
Table 15.30 Non-Opioid Drugs and Devices for Chronic Pain Management: Distribution by Type of Part
Table 15.31 Non-Opioid Drugs for Chronic Pain Management: Cumulative Number of Funding Instances,
Table 15.32 Non-Opioid Drugs for Chronic Pain Management: Cumulative Distribution of Amount Invest
Table 15.33 Non-Opioid Drugs for Chronic Pain Management: Distribution by Type of Funding (2010-20
Table 15.34 Non-Opioid Drugs for Chronic Pain Management: Distribution of Total Amount Invested by
Table 15.35 Non-Opioid Drugs for Chronic Pain Management: Most Active Players by Number of Funding
Table 15.36 Non-Opioid Drugs for Chronic Pain Management: Most Active Investors by Number of Fundi
Table 15.37 Non-Opioid Drugs for Chronic Pain Management: Funding and Investment Summary (USD Milli
Table 15.38 Non-Opioid Drugs for Chronic Pain Market: Base Scenario, 2018-2025 (USD Billion)
Table 15.39 Non-Opioid Drugs for Chronic Pain Market: Conservative Scenario, 2018-2025 (USD Billio
Table 15.40 Non-Opioid Drugs for Chronic Pain Management Market: Optimistic Scenario, 2018-2025 (U
Table 15.41 Non-Opioid Drugs for Chronic Pain Management Market: Distribution by Therapeutic Area,
Table 15.42 Non-Opioid Drugs for Chronic Pain Management Market: Distribution by Mechanism of Acti
Table 15.43 Non-Opioid Drugs for Chronic Pain Management Market: Distribution by Geography, 2018-2
Table 15.44 Qutenza® Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.45 Qutenza® Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.46 Qutenza® Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.47 Vimovo® Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.48 Vimovo® Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.49 Vimovo® Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.50 Duexis® Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.51 Duexis® Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.52 Duexis® Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.53 Gralise® Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.54 Gralise® Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.55 Gralise® Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.56 Horizant® Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.57 Horizant® Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.58 Horizant® Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.59 Zilretta® Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.60 Zilretta® Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.61 Zilretta® Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.62 Ztlido™ Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.63 Ztlido™ Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.64 Ztlido™ Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.65 Aimovig™ Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.66 Aimovig™ Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.67 Aimovig™ Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.68 Fremanezumab Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.69 Fremanezumab Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.70 Fremanezumab Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.71 Galcanezumab Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.72 Galcanezumab Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.73 Galcanezumab Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.74 Mirogabalin (DS-5565) Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.75 Mirogabalin (DS-5565) Sales Forecast (2018-2025):Conservative Scenario (USD Million)
Table 15.76 Mirogabalin (DS-5565) Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.77 YHD1119 Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.78 YHD1119 Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.70 YHD1119 Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.80 GLA5PR Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.81 GLA5PR Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.82 GLA5PR Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.83 Eptinezumab Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.84 Eptinezumab Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.85 Eptinezumab Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.86 ALLOD-2 Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.87 ALLOD-2 Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.88 ALLOD-2 Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.89 PainBrake® Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.90 PainBrake® Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.91 PainBrake® Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.92 Neridronate Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.93 Neridronate Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.94 Neridronate Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.95 Fasinumab Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.96 Fasinumab Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.97 Fasinumab Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.98 SP-102 Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.99 SP-102 Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.100 SP-102 Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.101 CNTX-4975 Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.102 CNTX-4975 Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.103 CNTX-4975 Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.104 MPC-06-ID Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.105 MPC-06-ID Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.106 MPC-06-ID Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.107 Tanezumab Sales Forecast (2018-2025): Base Scenario (USD Million)
Table 15.108 Tanezumab Sales Forecast (2018-2025): Conservative Scenario (USD Million)
Table 15.109 Tanezumab Sales Forecast (2018-2025): Optimistic Scenario (USD Million)
Table 15.110 Chronic Pain Management Devices Market: Base Scenario, 2018-2025 (USD Billion)
Table 15.111 Chronic Pain Management Devices Market: Conservative Scenario, 2018-2025 (USD Billion)
Table 15.112 Chronic Pain Management Device Market: Optimistic Scenario, 2018-2025 (USD Billion)
Table 15.113 Chronic Pain Management Device Market: Distribution by Geography, 2018-2025 (USD Billi
Table 15.114 Chronic Pain Management Device Market: Distribution by Type of Device, 2018-2025 (USD
Table 15.115 Chronic Pain Management Device Market: Distribution by Mechanism of Action, 2018-2025
Table 15.116 Non-Opioid Drugs for Chronic Pain Management Market: Summary of Base, Conservative and Optimistic Scenarios

List of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 1st Order Pharmaceuticals
  2. 23andMe
  3. 4P Therapeutics
  4. 6 Dimensions Capital
  5. Abbott
  6. AbbVie
  7. Abingworth 
  8. AcelRx Pharmaceuticals
  9. Achelios Therapeutics
  10. Acorda Therapeutics
  11. Actavis Generics
  12. AcuKnee
  13. Advanced Technology Ventures
  14. AdynXX
  15. Alder BioPharmaceuticals
  16. Algiax Pharmaceuticals
  17. Algorithm Technologies
  18. Alkermes
  19. Allergan
  20. Allodynic Therapeutics
  21. Almirall de Mexico
  22. Alta Partners
  23. American College of Rheumatology
  24. Amgen
  25. Amura Therapeutics
  26. Amway
  27. Anavex Life Sciences
  28. Angenieux 
  29. Anulex Technologies
  30. AppliedVR
  31. Aptinyx
  32. Araim Pharmaceuticals
  33. Arbor Pharmaceuticals 
  34. ARCH Venture Partners
  35. ArrowMark Partners
  36. Arteaus Therapeutics
  37. Astellas Pharma
  38. AstraZeneca
  39. Autonomic Technology
  40. Avacare Health
  41. AVACEN Medical
  42. Avanir Pharmaceuticals
  43. Axiobionics
  44. Axxam
  45. Bain Capital Life Sciences
  46. Bayer
  47. BDC Venture Capital
  48. BIAL
  49. BioCare Systems
  50. BioElectronics
  51. Biogen
  52. Biogen New Ventures
  53. BioHealthonomics
  54. Bioness
  55. BioVentures Investors
  56. BioWave 
  57. Bluegrass Angels
  58. BlueWind Medical
  59. Boehringer Ingelheim
  60. Boston Medical Investors
  61. Boston Scientific
  62. Bristol-Myers Squibb
  63. Calchan
  64. Calmare Therapeutics
  65. Calox de Costa Rica
  66. Canaan Partners
  67. Cara Therapeutics
  68. CDA Research Group
  69. Cedars-Sinai Medical Centre 
  70. Cefaly Technology
  71. Centrexion Therapeutics
  72. CerSci Therapeutics
  73. CEVEC Pharmaceuticals
  74. Chattem
  75. Clough Capital Partners
  76. Cmxtwenty
  77. Cold Laser Relief
  78. CoLucid Pharmaceuticals
  79. Commence Bio
  80. Concentric Analgesics
  81. Convergence Pharmaceuticals
  82. Cornell University
  83. Cosman Medical
  84. Crinetics Pharmaceuticals
  85. Cryopak
  86. Cross Creek Advisors
  87. CTI Life Sciences Fund
  88. Daewoong Pharmaceuticals
  89. Daiichi Sankyo
  90. DavaRay
  91. Deerfield Management
  92. Delphi Ventures
  93. Depomed 
  94. DermaXon
  95. Diamond Capital Management
  96. Dolphin Neurostim
  97. Domain Associates
  98. Dr. Reddy’s Laboratory
  99. Duke University
  100. DURECT Corporation
  101. Efung Capital
  102. Eisai
  103. electroCore
  104. ElectroMedical Technologies
  105. Electronic Wave Form Labs
  106. Eli Lilly
  107. ELvation Medical
  108. EMS
  109. eNeura
  110. Epimed International
  111. Epirus Biopharmaceuticals
  112. Esteve
  113. Eupraxia Pharmaceuticals
  114. Exogear
  115. Extrazell
  116. Federation of State Medical Boards
  117. Firsthand Technology
  118. Fisher Wallace Laboratories
  119. Flexion Therapeutics
  120. Flowonix
  121. Frazier Healthcare Partners
  122. Frontier Biotech
  123. Fukuda Denshi
  124. Fyrsta Innovations
  125. Galápagos
  126. Genentech
  127. GeneQuine Biotherapeutics
  128. Genesys Capital
  129. Genexbio
  130. Georgetown Translational Pharmaceuticals
  131. Gilead Sciences
  132. GiMer Medical
  133. GL PharmTech
  134. GlaxoSmithKline
  135. Global Life Science Ventures
  136. Gradient
  137. Green Park & Golf Ventures
  138. Grove Street Advisors
  139. Grünenthal
  140. GT Biopharma
  141. Haylard Health
  142. HBM Healthcare Investments
  143. Hema Enterprises
  144. Heptares Therapeutics
  145. Hercules Capital
  146. H.I.G Capital
  147. High-Tech Gründerfonds
  148. Hinge Health
  149. Horizon Pharma
  150. Humanitarian Innovation Fund
  151. Hungarian Academy of Sciences 
  152. Hydra Biosciences
  153. Immune Pharmaceuticals
  154. Incepta Pharmaceuticals
  155. InMed Pharmaceuticals
  156. Innovate UK
  157. Innovative Med Concepts
  158. Inspirion Delivery Sciences
  159. INSYS Therapeutics
  160. InterWest Partners
  161. InterX Technologies
  162. Iroko Pharmaceuticals
  163. Jeil Pharmaceuticals
  164. Johari Digital 
  165. Johnson & Johnson
  166. JT Pharmaceuticals
  167. KAI Pharmaceuticals
  168. KfW Group
  169. Kineta
  170. Knight Therapeutics
  171. Labrys Biologics (Subsidiary of Teva Pharmaceutical)
  172. Landsteiner Scientific
  173. Levicept
  174. Lexicon Pharmaceuticals
  175. LightStim
  176. Lilly Ventures
  177. Longitude Capital
  178. Lupin
  179. Mainstay Medical
  180. Mallinckrodt Pharmaceuticals
  181. Mapi Pharma
  182. Maxim Pharmaceuticals
  183. MAXONA Pharmaceuticals
  184. Mayo Clinic
  185. MD Biosciences
  186. Meagan Medical
  187. Med-Ally
  188. Medical Devices
  189. Medifron DBT
  190. MedImmune Ventures
  191. Medincell
  192. Medtronic
  193. Mensana Clinics Daignostics
  194. Merck
  195. Mesoblast
  196. Mitsubishi Tanabe Pharma 
  197. Moebius Medical
  198. Montreux Equity Partners
  199. Morulaa HealthTech
  200. Multisana
  201. Mundipharma
  202. Mylan
  203. MyoScience
  204. National Institute of Neurological Disorders and Stroke
  205. National Institute on Drug Abuse 
  206. National Institutes of Health 
  207. Neumentum
  208. Neuraxon
  209. NeurAxon Pharma
  210. NeuroVentures
  211. Neuro Vigor
  212. NeurogesX
  213. NeuroMetrix
  214. NeurOp
  215. Neuros Medical
  216. Neurova
  217. Nevro
  218. New Enterprise Associates
  219. New Jersey Packaging Executives Club
  220. New Leaf Venture Partners
  221. Newron Pharmaceuticals
  222. Nice & Green
  223. Nicox
  224. Novaremed
  225. Novartis
  226. NuPathe
  227. Nuvectra
  228. Nuvo Pharmaceuticals
  229. Octusa Spine
  230. Oculus
  231. Ogeda
  232. OliPass
  233. OMRON Healthcare
  234. Optimus Medical
  235. Optinose
  236. Orbimed Advisors
  237. Osage University
  238. Oska Wellness
  239. Otsuka Pharmaceutical
  240. PainPod BioTechnology
  241. Pamoja Capital
  242. Par Pharmaceutical 
  243. Patheon
  244. PeriphaGen
  245. Pfizer
  246. Pharmaleads
  247. Polaris Partners
  248. POZEN 
  249. Prismic Pharmaceuticals
  250. Prizm Medical
  251. Proximagen
  252. PT Pratapa Nirmala (Renamed to Fahrenheit)
  253. Pulse Laser Relief 
  254. Purdue Pharma
  255. Quan Capital
  256. Reata Pharmaceuticals 
  257. Recro Pharma
  258. Regenacy Pharmaceuticals
  259. Regeneron Pharmaceuticals
  260. Regulonix
  261. Relief Therapeutics
  262. Relievant Medsystems
  263. Renewal Technologies
  264. Ritmedic
  265. Roche
  266. Saluda Medical
  267. Samsung Electronics America
  268. Samyang Biopharmaceuticals
  269. Saniona
  270. Sanofi
  271. Scenarworld
  272. Scintilla Pharmaceuticals
  273. Semnur Pharmaceuticals
  274. Servier
  275. Shionogi
  276. Silk'n Therapy
  277. Solasia Pharma
  278. Sorrento Therapeutics
  279. Sosei Group
  280. Sphaera Pharma
  281. SPR Therapeutics
  282. St. Jude Medical
  283. StimRelieve
  284. Stimwave Technologies
  285. SUBLIMED
  286. Sumitomo Dainippon Pharma
  287. Sun Pharmaceutical Industries
  288. Sutter Hill Ventures 
  289. SV Health Investors
  290. SWITCH Biotech
  291. SyroLight
  292. Teachers Insurance and Annuity Association
  293. Teikoku Pharma
  294. TENS Rx
  295. Teva Pharmaceutical Industries
  296. Thar Pharmaceuticals
  297. The Apex Practice
  298. The Ontario Capital Growth 
  299. Theravance Biopharma 
  300. Toray Industries
  301. TPG Biotech
  302. Trigemina
  303. TÅ°V SÅ°D
  304. UCB Pharma
  305. University of North Carolina
  306. Upsher-Smith  Laboratories
  307. Valeant Pharmaceuticals
  308. Vanway 
  309. Vapogenix
  310. Vault Bioventures
  311. Ventures West Capital
  312. Vertex Pharmaceuticals
  313. ViaTherm Therapeutics
  314. Virobay
  315. Vista Healthcare Technologies
  316. Virtual Reality Medical Centre
  317. Visualase
  318. Vital Motion
  319. Vivo Capital
  320. Walden International
  321. Wasatch Advisors
  322. WEX Pharmaceuticals
  323. WinSanTor
  324. Winston Pharmaceuticals
  325. Xavant Technology
  326. Xenon Pharma
  327. XenoPort 
  328. Yuhan 
  329. Zalicus
  330. Zydus Pharmaceuticals 
  331. Zynex Medical

PRICING DETAILS

USD 3,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.